In 2016 the Bill and Melinda Gates Foundation sought out Mologic as its partner to engage in the development of a new high-sensitivity technology platform for rapid diagnostic applications. The collaboration called CARD, the Centre of Advanced Rapid Diagnostics, recently delivered on its first milestone objective of a platform that can measure protein antigenic targets down to 1pg/ml without the need for a reader or other technology, the firm said. This firm anticipates that the technology will be made available to clients during 2019, along with a tailored development service.
Mologic has raised £7 million since 2015 from enterprise investment scheme and venture capital trust investors in the UK.
In April, the firm announced that it had inked an agreement with PATH, an international nonprofit with a focus on improving health, to advance a new rapid diagnostic test to support treating and eliminating Plasmodium vivax malaria.
In May, the firm inked European distribution agreements for its Periplex point-of-care test for detection of infections in patients undergoing peritoneal dialysis.
Also in May, Mologic received a £4 million Series B investment that came from funds managed by Foresight Group with existing investor Calculus Capital.
Fraunhofer UK Research is working with the firm to develop a new microfluidics-based test to not only identify if bacteria causing urinary tract infections are present, but to gauge their resistance to different antibiotic treatments. NHS England recently awarded the project roughly £900,000 following an initial investment of £92,000 in April 2017.
In his efforts to introduce Mologic’s products in North America, Fletcher is focused on understanding the difference in the dynamics of the North America market versus those of Europe and particularly the UK. “The whole idea is to obtain a better understanding of the reimbursement and regulatory landscapes and ultimately the uptake of the products, their value proposition, and their positioning,” he said in an interview.
Pricing or products has yet to be determined, Mark Davis said, but given that its systems use lateral flow technology and inexpensive readers, they will be favorably priced compared with other emerging technologies such as molecular diagnostics, he said.
Mologic is currently seeking US-based clinical and key opinion leader partners, he added.